Karo Pharma acquires Trimb AB
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
UK biotech to make proteins from carbon dioxide emissions
Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.
GM proponents grill German government
German GM proponents have taken action against discrimination of food products generated by gene editing.
Human cell chip predicts chemotherapy effects
Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.
IL-10R-deficient macrophages trigger IBD
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Breakthrough in liquid biopsy
German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
ADC Therapeutics raise $76m in Series E expansion
Swiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.
Janssen and Genmab in licence option deal
Janssen Biotech Inc has inked a licence option contract with Genmab A/S on its next-generation anti CD38 antibody HexaBody®-CD38 and HexaBody platform technology.
HRP-Protector – for easy and safe long-term storage of HRP conjugates
HRP-Protector is a long-term stabilizer for horseradish peroxidase (HRP) coupled to antibodies or Neutravidin/Streptavidin.
Evotec bags US$23.8m to fight tuberculosis
The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.